This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Oct 10;28(29):e560-1; author reply e562.

doi: 10.1200/JCO.2010.29.5170. Epub 2010 Aug 30.

Abiraterone acetate is well tolerated without concomitant use of corticosteroids

Gerhardt Attard, Alison H M Reid, Johann S de Bono

PMID: 20805462
DOI: 10.1200/JCO.2010.29.5170

Comment

Abiraterone acetate is well tolerated without concomitant use of corticosteroids

Gerhardt Attard et al. J Clin Oncol. 2010.

. 2010 Oct 10;28(29):e560-1; author reply e562.

doi: 10.1200/JCO.2010.29.5170. Epub 2010 Aug 30.

Authors

Gerhardt Attard, Alison H M Reid, Johann S de Bono

PMID: 20805462
DOI: 10.1200/JCO.2010.29.5170

No abstract available

PubMed Disclaimer

Comment on

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. Ryan CJ, et al. J Clin Oncol. 2010 Mar 20;28(9):1481-8. doi: 10.1200/JCO.2009.24.1281. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159824 Free PMC article. Clinical Trial.

Similar articles

Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2011 Aug 25;53(1370):63-4. Med Lett Drugs Ther. 2011. PMID: 21836546 Review. No abstract available.
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, de Bono JS. Attard G, et al. J Clin Endocrinol Metab. 2012 Feb;97(2):507-16. doi: 10.1210/jc.2011-2189. Epub 2011 Dec 14. J Clin Endocrinol Metab. 2012. PMID: 22170708 Clinical Trial.
Abiraterone and increased survival in metastatic prostate cancer.
Berruti A, Pia A, Terzolo M. Berruti A, et al. N Engl J Med. 2011 Aug 25;365(8):766; author reply 767-8. doi: 10.1056/NEJMc1107198. N Engl J Med. 2011. PMID: 21864182 No abstract available.
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
Omlin A, Pezaro CJ, Zaidi S, Lorente D, Mukherji D, Bianchini D, Ferraldeschi R, Sandhu S, Dearnaley D, Parker C, Van As N, de Bono JS, Attard G. Omlin A, et al. Br J Cancer. 2013 Sep 3;109(5):1079-84. doi: 10.1038/bjc.2013.446. Epub 2013 Aug 8. Br J Cancer. 2013. PMID: 23928659 Free PMC article.
Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
Salem M, Garcia JA. Salem M, et al. Curr Oncol Rep. 2011 Apr;13(2):92-6. doi: 10.1007/s11912-011-0153-4. Curr Oncol Rep. 2011. PMID: 21243537 Review.

See all similar articles

Cited by

Constitutive and treatment-induced CXCL8-signalling selectively modulates the efficacy of anti-metabolite therapeutics in metastatic prostate cancer.
Wilson C, Maxwell PJ, Longley DB, Wilson RH, Johnston PG, Waugh DJ. Wilson C, et al. PLoS One. 2012;7(5):e36545. doi: 10.1371/journal.pone.0036545. Epub 2012 May 9. PLoS One. 2012. PMID: 22590561 Free PMC article.
Small Mitochondria-Targeting Fluorophore with Multifunctional Therapeutic Activities against Prostate Cancer via the HIF1α/OATPs Pathway.
Qin J, Zhang C, Zhao Y, Tan D, Wu P, Shui X, Qin W, Ge X, Shi C. Qin J, et al. Mol Pharm. 2023 Dec 4;20(12):6226-6236. doi: 10.1021/acs.molpharmaceut.3c00621. Epub 2023 Nov 13. Mol Pharm. 2023. PMID: 37955533 Free PMC article.
Cardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review.
Zullig LL, Sung AD, Khouri MG, Jazowski S, Shah NP, Sitlinger A, Blalock DV, Whitney C, Kikuchi R, Bosworth HB, Crowley MJ, Goldstein KM, Klem I, Oeffinger KC, Dent S. Zullig LL, et al. JACC CardioOncol. 2022 Jun 21;4(2):149-165. doi: 10.1016/j.jaccao.2022.03.005. eCollection 2022 Jun. JACC CardioOncol. 2022. PMID: 35818559 Free PMC article. Review.
Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate.
Sundar S, Dickinson PD. Sundar S, et al. BMJ Case Rep. 2012 Feb 25;2012:bcr1120115238. doi: 10.1136/bcr.11.2011.5238. BMJ Case Rep. 2012. PMID: 22665559 Free PMC article.
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer.
Knudsen KE, Kelly WK. Knudsen KE, et al. Expert Rev Endocrinol Metab. 2011 May;6(3):483-493. doi: 10.1586/eem.11.33. Expert Rev Endocrinol Metab. 2011. PMID: 22389648 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information